Clinicopathologic Study on Clear Cell Hepatocellular Carcinoma.
- Author:
Min Kwan KANG
1
;
Hyuk Joon LEE
;
Sung Hwan CHANG
;
Seok Ho CHOI
;
Kyung Suk SUH
;
Kuhn Uk LEE
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. kssuh@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Clear cell hepatocellular carcinoma;
Hepatocellular carcinoma
- MeSH:
Carcinoma, Hepatocellular*;
Cytoplasm;
Eosine Yellowish-(YS);
Hematoxylin;
Hope;
Liver;
Liver Cirrhosis;
Portal Vein;
Prognosis;
Seoul;
Survival Rate
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2002;6(2):128-131
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Clear cell hepatocelluar carcinoma (CHCC) is a well defined type of hepatocellular carcinoma (HCC) in which a large number of tumor cells have clear cytoplasm that is not stained by hematoxylin and eosin stain. It is generally reported that CHCC has a favorable prognosis compared with that of conventional non-CHCC.1 The reasons for the better prognosis are not clear. To date the clinicopathologic features of CHCC of the liver have not been fully elucidated. In the present study we compared the clinicopathologic features of 56 cases of CHCC with those of 479 cases of non-CHCC and report here hoping to further understanding of CHCC. METHODS: 535 consecutive cases that were curatively resected from Jan. 1992 to Dec. 1997 in Seoul National University Hospital were reviewed. The cases were divided into clear cell HCC (56 cases) and non-clear cell HCC (479 cases). Clinical and pathological findings were compared between two groups. RESULTS: Clinically there is no significant difference in sex < age, preoperative liver function, the association rate with liver cirrhosis, the extent of resection. Pathologically there is no significant difference in tumor size, capsule formation, portal vein invasion, the differentiation of tumor. Three- and five- year survival rates of clear cell HCC were 55.3%, 42.8%, respectively, lower than the finding of 68.4%, 54.4% for non-clear cell HCC. But there is no significant difference in prognosis between both groups (p=0.13). The multiplicity rate (tumor number> or =2) of clear cell HCC was 3.8% (2/56), lower than the finding of 13.1% (62/479) for non-clear cell HCC. (p<0.05) CONCLUSION: It was concluded that clear cell HCC has no significant difference in clinicopathologic features except tumor number.
